Ginkgo Bioworks Holdings Inc (DNA)
0.8705
+0.03
(+3.29%)
USD |
NYSE |
Apr 23, 16:00
0.8888
+0.02
(+2.10%)
Pre-Market: 04:27
Ginkgo Bioworks Holdings Cash from Financing (TTM): -3.216M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -3.216M |
| September 30, 2023 | 95.18M |
| June 30, 2023 | 95.10M |
| March 31, 2023 | 95.64M |
| December 31, 2022 | 95.34M |
| Date | Value |
|---|---|
| September 30, 2022 | -13.47M |
| June 30, 2022 | 1.535B |
| March 31, 2022 | 1.533B |
| December 31, 2021 | 1.534B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-13.47M
Minimum
Sep 2022
1.535B
Maximum
Jun 2022
551.86M
Average
95.34M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
| Agenus Inc | 119.87M |
| Teladoc Health Inc | 10.85M |
| Sarepta Therapeutics Inc | 125.00M |
| Ultragenyx Pharmaceutical Inc | 388.14M |
| Apellis Pharmaceuticals Inc | 394.50M |